3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
179
Lung Neoplasms
62
Neoplasms
24
Neoplasm Metastasis
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Mesothelioma, Malignant
12
Carcinoma
12
Colorectal Neoplasms
10
Mesothelioma
9
Meningeal Carcinomatosis
8
Melanoma
8
Brain Neoplasms
7
Pancreatic Neoplasms
6
Adenocarcinoma of Lung
6
Ovarian Neoplasms
5
Advanced Solid Tumors
5
Uterine Cervical Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms by Site
4
NSCLC
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Non-squamous Non-small Cell Lung Cancer
3
Neoplasms by Histologic Type
3
Lung Diseases
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Bronchogenic
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Interventions
pembrolizumab
2
Pemetrexed
1
MRX-2843
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Pemetrexed
×
1 year
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled